153 related articles for article (PubMed ID: 22622596)
21. Universal childhood immunisation with pneumococcal vaccine and meningococcal serogroup C vaccine introduced in Germany.
Wiese-Posselt M; Hellenbrand W; Siedler A; Mayer C
Euro Surveill; 2006 Sep; 11(9):E060907.4. PubMed ID: 17075143
[No Abstract] [Full Text] [Related]
22. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
[TBL] [Abstract][Full Text] [Related]
24. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.
Lawrence GL; Wang H; Lahra M; Booy R; McINTYRE PB
Epidemiol Infect; 2016 Aug; 144(11):2382-91. PubMed ID: 27094814
[TBL] [Abstract][Full Text] [Related]
25. Evolving meningococcal immunization strategies.
Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
[TBL] [Abstract][Full Text] [Related]
26. [Mass vaccination campaign against serogroup C meningococcal disease, municipality of Itapeva, Sao Paulo].
Centro de Vigilância Epidemiológica Prof. Alexandre Vranjac, Secretaria de Estado da Saúde de São Paulo
Rev Saude Publica; 2005 Feb; 39(1):139-40. PubMed ID: 15654472
[No Abstract] [Full Text] [Related]
27. Meningococcal serogroup C conjugate vaccination in Canada: how far have we progressed? How far do we have to go?
White CP; Scott J
Can J Public Health; 2010; 101(1):12-4. PubMed ID: 20364530
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
[TBL] [Abstract][Full Text] [Related]
29. Long-term impacts of MenC vaccination campaign in the Salvador, Brazil metropolitan region: A comparison of pre- and post-vaccine periods.
Monalisa Mendes Dantas Sales N; Azevedo J; Teles Bastos Ribeiro M; Fonseca de Freitas H; Pedreira da Silva Filho H; Machado Cordeiro S; Galvão Reis M; Neves Reis J
Vaccine; 2020 Sep; 38(40):6267-6273. PubMed ID: 32741673
[TBL] [Abstract][Full Text] [Related]
30. Meningococcal conjugate vaccines.
Zimmer SM; Stephens DS
Expert Opin Pharmacother; 2004 Apr; 5(4):855-63. PubMed ID: 15102568
[TBL] [Abstract][Full Text] [Related]
31. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
[TBL] [Abstract][Full Text] [Related]
32. Impact of serogroup A meningococcal conjugate vaccine for Africa.
Stuart JM
Hum Vaccin Immunother; 2018 May; 14(5):1116-1117. PubMed ID: 29194010
[TBL] [Abstract][Full Text] [Related]
33. Global practices of meningococcal vaccine use and impact on invasive disease.
Ali A; Jafri RZ; Messonnier N; Tevi-Benissan C; Durrheim D; Eskola J; Fermon F; Klugman KP; Ramsay M; Sow S; Zhujun S; Bhutta Z; Abramson J
Pathog Glob Health; 2014 Jan; 108(1):11-20. PubMed ID: 24548156
[TBL] [Abstract][Full Text] [Related]
34. Impact of vaccination on meningococcal epidemiology.
Stefanelli P; Rezza G
Hum Vaccin Immunother; 2016 Apr; 12(4):1051-5. PubMed ID: 26512927
[TBL] [Abstract][Full Text] [Related]
35. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ
PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448
[TBL] [Abstract][Full Text] [Related]
36. Immunization strategies for the control of serogroup C meningococcal disease in developed countries.
De Wals P
Expert Rev Vaccines; 2006 Apr; 5(2):269-75. PubMed ID: 16608426
[TBL] [Abstract][Full Text] [Related]
37. Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo(®)): profile report.
Deeks ED
Paediatr Drugs; 2012 Feb; 14(1):63-5. PubMed ID: 22149552
[No Abstract] [Full Text] [Related]
38. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
Soriano-Gabarró M; Rosenstein N; LaForce FM
J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
[TBL] [Abstract][Full Text] [Related]
39. The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines.
Pelton SI
J Adolesc Health; 2016 Aug; 59(2 Suppl):S3-S11. PubMed ID: 27449148
[TBL] [Abstract][Full Text] [Related]
40. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
